The therapeuatic effect of Endostar on soft carotid plaque neovascularization in patients with non-small cell lung cancer.
The purpose of this study was to investigate the effect of the angiogenesis inhibitor Endostar on carotid plaque neovascularization in patients with non-small cell lung cancer (NSCLC) using contrast-enhanced ultrasound (CEUS). Ninety-one patients who had NSCLC with soft carotid plaques were selected for treatment either with the NP regimen (vinorelbine + cisplatin) (43 patients) or with the ENP regimen (Endostar + NP) (48 patients). Plaque thickness and neovascularization of the plaque were assessed before and at 1 month after treatment using CEUS. Enhanced intensity (EI) of CEUS was used for quantification of plaque neovascularization. There was no significant changes in any group in thickness of plaque between recruitment and 1 month after treatment (P > 0.05 for all). There was no significant change in the EI of plaque in the controls or NP groups at 1 month after treatment (P > 0.05), while EI in the ENP group was significantly reduced at 1 month after treatment (P < 0.01) and significantly lower than that in the controls or NP group at 1 month after treatment (P < 0.001 both). This study indicates that carotid soft plaque neovascularization in patients with NSCLC can be reduced by anti-angiogenesis treatment.
Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China.
Zhaoxia
Z
Pu
Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China.
Yao
Y
Wang
Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China.
Ying
Y
Zhang
Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China.
Jing
J
Huang
Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China.
Yurong
Y
Hong
Department of Ultrasound, the Second Affiliated Hospital of Wenzhou Medical University, Zhejiang 325027, China.
Huiliao
H
He
Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China.
Chunmei
C
Liu
Baylor Heart &Vascular Institute, Baylor University Medical Center, 621 N. Hall St., Suite H030 Dallas, Texas 75226, USA.
Shuyuan
S
Chen
Baylor Heart &Vascular Institute, Baylor University Medical Center, 621 N. Hall St., Suite H030 Dallas, Texas 75226, USA.
Paul A
PA
Grayburn
1] Department of Ultrasound, the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang 310009, China [2] Department of Ultrasound, the Second Affiliated Hospital of Wenzhou Medical University, Zhejiang 325027, China.
Pintong
P
Huang
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D002339:Carotid Arteries / Q000187:drug effects / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003287:Contrast Media; D043169:Endostatins / Q000008:administration & dosage* / Q000235:genetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D058226:Plaque, Atherosclerotic / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011994:Recombinant Proteins; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077235:Vinorelbine
D020533:Angiogenesis Inhibitors; D003287:Contrast Media; D043169:Endostatins; D011994:Recombinant Proteins; D014747:Vinblastine; C522911:endostar protein; D002945:Cisplatin; D000077235:Vinorelbine